Munich Leukemia Laboratory Selects IBM Watson and Illumina for Research Collaboration to Advance Dia

IBM press release ----- Munich Leukemia Laboratory (MLL), a state-of-the-art leukemia and lymphoma diagnostic and research laboratory based in Munich, has teamed up with IBM (NYSE: IBM) and Illumina, Inc. (NASDAQ: ILMN) to help build a new cognitive technology prototype that aims to help researchers improve leukemia treatment. The prevalence of leukemia is on the rise in Europe, with 15,000 new diagnoses each year in Germany alone. MLL will use NovaSeq technology from Illumina, the global leader in next-generation sequencing technology, to sequence samples from its biobank of more than 500,000 cases. MLL researchers then plan to use Watson to help analyze the genomic data alongside other data sources. The project intends to include innovative testing processes such as automated phenotyping and genotyping including whole genome sequencing (WGS) and transcriptome sequencing (RNASeq) in 5,000 cases. For more in depth information click on the picture below to read the release.